Yahoo Sports' Krysten Peek breaks down the top NBA prospects.
Yahoo Sports' Krysten Peek breaks down the top NBA prospects.
Dow Jones futures in were focus late Tuesday after the Dow Jones Industrial Average crossed 30,000 for the first time ever.
A spokeswoman for YouTube, the video-sharing platform owned by Alphabet's Inc's Google, said OAN had also been suspended from monetizing its videos due to repeated violations of the COVID-19 misinformation policy and other rules. OAN will have to reapply to be allowed to monetize again. President Donald Trump has promoted OAN, calling it a "great alternative" to Fox News in a tweet this month.
Hall of Fame manager Tom Lasorda’s condition has improved while he remains hospitalized in Southern California. Los Angeles Dodgers spokesman Steve Brener said Tuesday that the team's 93-year-old former manager has been taking online calls from former players and coaches at a hospital in Orange County. Lasorda attended the team’s Game 6 victory over the Tampa Bay Rays on Oct. 27 in Texas that clinched the Dodgers’ first World Series title since 1988.
‘America first – shouldn’t go away from that,’ outgoing president says, offering some advice to his replacement
The three-term Democratic governor also said layoffs, spending cuts and borrowing would be necessary to fill the budget hole.
Here's the best live laptop deals from Amazon, Best Buy, B&H; Photo Video, Walmart, Target, Apple, HP, Dell, and more.
For its second quarter ended October 11, 2020, Alimentation Couche-Tard Inc. ("Couche-Tard" or the "Corporation") (TSX: ATD.A) (TSX: ATD.B) announces net earnings attributable to shareholders of the Corporation of $757.0 million, representing $0.68 per share on a diluted basis. The results for the second quarter of fiscal 2021 were affected by a pre-tax gain on disposal of $40.9 million related to the sale of a property located in Toronto, Canada, a pre-tax net foreign exchange loss of $8.9 million, as well as pre-tax acquisition costs of $1.2 million. The results for the comparable quarter of fiscal 2020 were affected by a pre-tax net foreign exchange gain of $11.8 million, pre-tax acquisition costs of $0.8 million, as well as a tax benefit from the second tranche of the December 2018 asset exchange agreement with CAPL, of which $0.7 million was attributable to shareholders of the Corporation. Excluding these items, the adjusted net earnings were approximately $735.0 million1 or $0.661 per share on a diluted basis for the second quarter of fiscal 2021, compared with $569.0 million1 or $0.501 per share on a diluted basis for the second quarter of fiscal 2020, an increase of 32.0% in the adjusted net earnings per share on a diluted basis, driven by strong growth in merchandise and service and in road transportation fuel gross profit, as well as by good cost control. All financial information presented is in US dollars unless stated otherwise.
Ciro Immobile scored twice on his return to the Champions League after missing two games with the coronavirus as Lazio beat Zenit St. Petersburg 3-1 Tuesday. Appearing in the group phase for the first time in 13 years, Lazio remained second in Group F, one point behind Borussia Dortmund, which beat Club Brugge 3-0 in the other group game. Marco Parolo made it 2-0 for Lazio after 22 minutes with a low shot from near the same spot as Immobile's goal.
A shorter quarantine period is likely to include increased testing.
The therapy know as convalescent plasma, which delivers antibodies from COVID-19 survivors to infected people, did not significantly improve patients' health status or reduce their risk of dying from the disease any better than a placebo, the study published in The New England Journal of Medicine found. Despite limited evidence of its efficacy, convalescent plasma, which U.S. President Donald Trump touted in August as a "historic breakthrough," has been frequently given to patients in the United States. In October, a small study from India suggested convalescent plasma improved symptoms in COVID-19 patients, such as shortness of breath and fatigue, but did not reduce the risk of death or progression to severe disease after 28 days.
One America News Network has been banned for YouTube for one week after posting a bogus video about a cure for COVID-19. The far-right network, which has been an outspoken backer of President Donald Trump, will not be allowed to post original video and has been unplugged from the platform’s revenue-producing partner setup during the […]
Alexco Resource Corp. (NYSE American: AXU) (TSX: AXU) ("Alexco" or the "Company") is pleased to announce commissioning of the Keno Hill District Mill (the "Mill") commencing as scheduled, with initial production of lead/silver and zinc concentrates underway. The initial ore source for Mill commissioning is the Bellekeno underground mine where drilling, blasting and extraction of ore from long hole stopes continues.
Shares of Dycom (NYSE: DY) have gotten crushed today, closing down by 16%, after the company reported fiscal third-quarter earnings. Revenue in the fiscal third quarter came in at $810.3 million, which was below the consensus estimate of $817.7 million. Wall Street analysts were modeling for $1.05 per share in adjusted profits.
One company thinks "social media listening" is the answer to better predicting election outcomes.
Dad had to come in and break this up before it got out of hand. Crazy! Credit: Marissa Gendron Instagram: @marissagendron
Hot oil and an open flame can be a dangerous combination, but here's how to make frying a turkey safer this holiday season.
Wall Street tech giants anchor the office space business, rental concessions gone wild, FHFA boosts loan-purchase limits, Small Business Saturday could bring gloom, amusement parks may soon again zoom. The Wall Street Journal reports today that the biggest U.S. tech companies are providing a jolt to the slumbering commercial real estate business, emerging as major tenants and acquirers of office and other space -- while many nontech firms are trying to tear up their leases. Rental Beast says the surging coronavirus and new lockdowns, expiring government stimulus programs, and colder weather has set off a rental concessions bonanza in U.S. markets, as property managers, owners, agents, and tenants struggle to navigate continued volatility while securing housing plans before year's end.
Toronto, Ontario--(Newsfile Corp. - November 24, 2020) - Galleon Gold Corp. (TSXV: GGO) (the "Company" or "Galleon Gold") is pleased to announce that all of the resolutions put forth at the Annual and Special Meeting of Shareholders (the "Meeting") held on November 24, 2020 were approved. At the Meeting, shareholders elected the following directors to hold office for the ensuing year: R. David Russell, Christian Dupont, Thomas Kofman, James T. O'Neil Jr., Mario Colantonio, ...
TORONTO, Nov. 24, 2020 /CNW/ - Fidelity Investments Canada ULC ("Fidelity") today announced the estimated 2020 annual reinvested capital gains distributions for Fidelity's suite of ETFs ("Fidelity ETFs").
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) completed its internal review of the Baseline-Controlled Study results of omaveloxolone for the treatment of patients with Friedreich’s ataxia (“FA”) and concluded that the results do not strengthen the results of Part 2 of the MOXIe study. The FDA proposed some additional exploratory analyses using patients randomized to placebo during the MOXIe Part 2 study, but stated that the potential for these analyses to strengthen the study results was questionable due to the small number of patients available for analysis. The FDA stated that they remain interested in reviewing the results of the additional exploratory analyses as those may inform the future development program. The Company plans to submit to the FDA the analyses that they proposed and to request a meeting with the FDA to discuss the development program. In addition, based on the FDA’s conclusion, the Company is considering the next steps for the development program, including whether to conduct a second pivotal study in patients with FA.“Omaveloxolone improved motor function as measured by the modified Friedreich’s Ataxia Rating Scale in both Part 2 of the MOXIe study and the Baseline-Controlled study. We are grateful to the families, physicians, investigators, and advocates who have supported this program to date,” said Warren Huff, Reata’s Chairman and Chief Executive Officer. “Though we are disappointed in the FDA’s feedback on this program, we will carefully consider the potential paths forward for making omaveloxolone available to patients with FA.”About Friedreich's AtaxiaFA is a rare, inherited, life-shortening, debilitating, and degenerative neuromuscular disorder, which is normally diagnosed during adolescence. FA is typically caused by a trinucleotide repeat expansion in the first intron of the frataxin gene, which encodes the mitochondrial protein frataxin. Pathogenic repeat expansions can lead to impaired transcription and reduced frataxin expression, which can lead to mitochondrial iron overload and poor cellular iron regulation, increased sensitivity to oxidative stress, and impaired mitochondrial ATP production. Patients with FA experience initial symptoms in childhood, including progressive loss of coordination, muscle weakness, and fatigue, commonly resulting in motor incapacitation, with patients requiring a wheelchair by their teens or early 20s. FA patients may also experience visual impairment, hearing loss, diabetes, and cardiomyopathy. Based on literature and proprietary research, we believe FA affects approximately 5,000 children and adults in the United States and 22,000 individuals globally. There are currently no approved therapies for the treatment of FA.About OmaveloxoloneOmaveloxolone is an investigational, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug designation to omaveloxolone for the treatment of Friedreich’s ataxia. The European Commission has granted Orphan Drug designation in Europe to omaveloxolone for the treatment of Friedreich’s ataxia. About Reata Pharmaceuticals, Inc.Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.Contact: Reata Pharmaceuticals, Inc. (972) 865-2219 http://reatapharma.comInvestor Relations Vinny Jindal (469) email@example.com http://reatapharma.com/contact-us/Forward-Looking StatementsThis press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including the detailed factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.